USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CEL-SCI CORPORATION
Address:
CEL-SCI CORPORATION
8229 BOONE BLVD, STE 802
VIENNA, VA 22182
Phone:
(703) 506-9460
URL:
EIN:
840916344
DUNS:
102560141
Number of Employees:
44
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $500,692.00 5
SBIR Phase II $379,053.00 1

Award List:

HETEROCONJUGATE VACCINES AGAINST HERPES SIMPLEX VIRUS

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Zimmerman, Daniel H
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Daniel H. Zimmerman
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$379,053.00
Agency:
HHS
Principal Investigator:
Daniel H. Zimmerman
Abstract:
N/a

Augmenting innate and vaccine immune response with der-G

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$104,091.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Concerns regarding the United States' vulnerability to a terrorist attack with smallpox have stimulated development of new vaccines, prophylactics and therapeutics. However, a new and successful smallpox vaccine intervention program, or one to treat exposed… More

derG Immunostimulant Prevention/Treatment of HSV Disease

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$162,132.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by the applicant): The goal of this program is to develop derG as a therapeutic and/or prophylactic agent for HSV infections. DerG is a small peptide shown in preliminary experiments to elicit anti-viral and anti-parasitic (malarial) responses, and adjuvant activity. Based… More

Peptide Vaccine for Experimental Autoimmune Myocarditis

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$134,469.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by the applicant): In A/J Mice Experimental Autoimmune Myocarditis (EAM) can be induced by infection with coxsackie virus B 3 or by immunization with murine or porcine cardiac myosin or a cardiogenic peptide from the murine cardiac myosin (My-l). In all these three cases the… More